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Recent advances in nanotechnology, biotechnology, bioinformatics, and materials science have prompted novel 
developments in the field of nanomedicine. Enhancements in the theranostics, computational information, and 
management of diseases/disorders are desperately required. It may now be conceivable to accomplish checked 
improvements in both of these areas utilising nanomedicine. This scientific and concise review concentrates on the 
fundamentals and potential of nanomedicine, particularly nanoparticles and their advantages, nanoparticles for siRNA 
conveyance, nanopores, nanodots, nanotheragnostics, nanodrugs and targeting mechanisms, and aptamer nanomedicine. 
The combination of various scientific fields is quickening these improvements, and these interdisciplinary endeavours 
to have significant progressively outstretching influences on different fields of research. The capacities of nanomedicine 
are immense, and nanotechnology could give medicine a completely new standpoint.  
 





The first utilisation of the trademark frameworks in ‘nano-
technology' (but preceding use of that name) was in 
"There's Plenty of Room at the Bottom," a speech given by 
physicist Richard Feynman at an American Physical 
Society meeting at Caltech on December 29, 1959.1 
Nanotechnology refers broadly to a field of applied 
science and technology whose unifying theme is the 
control of matter on the molecular level in scales smaller 
than 1 micrometer, normally 1 to 100 nanometers, and 
the fabrication of devices within that size range.2 Nano-
medicine is the design and development of theranostics 
tools diverged by the nanoscopic scale of its delivery 
vehicles and diagnostic agents.3,4 Briefly, Nanomedicine 
is an applied, practiced, and utilised nanotechnology in 
the field of medicine.5  
 
Nanomedicine has provided some novel explanations and 
solutions. There are a lot of pharmaceutical companies 
endeavouring to advance targeted drug delivery using 
nanotechnology. Some of the existing drugs based on 
nanotechnology have the potential to revolutionise our 
understanding of human health and disorders. It also 
offers an assurance of a transformed portrait of better 
health care, health economics, and personalised medicine, 
with the eventual aim being an upgraded quality-of-life.6 
Advances in the progression of lipid-based nanome 
dicine, nanostructured drugs with effective site-targeting, 
nanopharmaceuticals, nano-imaging, nanoplat forms, nano-
theranostics and nano-drug delivery, nano-immunochemo-
therapy, and post-nano approaches [such as multistage 
vector (MSV) platform] will run and enhance the future 
development of nanomedicine, personalised medicine, 
and targeted therapy.7–10  
 
Nanoparticles. Nanoparticles (NPs) are particles, typically 
less than 200 nm in diameter, which usually comprise of 
lipids or polymers. NPs are capable of delivering drugs 
over epi-endothelial barriers and spatially limit through 
active-passive targeting.11 Polyvalent ornament of an 
NP's surface with a ligand can assuage binding to a 
biomarker that is particularly overrepresented in 
targeted cells, and activate receptor-mediated 
endocytosis. It has extensive significance for targeted 
delivery. The ligands used to adjust NPs include 
antibodies, aptamers, engineered antibody fragments, 
peptides, proteins, and small molecules.12,13 
 
Some of the NPs are elucidated herein. Arginine–glycine–
aspartate-grafted NPs can target avb3 integrin over-
expressed by the tumour endothelium, and extravasate 
more conveniently. They invade the tumour through the 
retention effect and augment permeability.14 A 
nanomedicine contrived of pegylated chitosan NPs with 
conjugated anti-transferrin receptor antibodies are able 
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to carry a blood–brain-barrier-impermeable caspase 
inhibitor to the brain.15 The arrangement of solid lipid 
NPs are laminated with the mucoadhesive polymer chi-
tosan for intestinal absorption of insulin.16-18  Application 
of nanocrystalline solid dispersions, PEG-PLGA NPs, 
nanoparticle precipitates, particles, and liposomes can 
be applied for the management of pulmonary arterial 
hypertension.19-20  
 
Benefits of Nanoparticles. Benefits include the advan-
cement of nanoparticles for screening and theranostics 
purposes, DNA sequencing applying nanopores, manu-
facture of drug delivery systems and single-virus detection, 
the significance and current advances in gene/drug delivery 
to cancer cells, the molecular imaging and diagnosis of 
cancer by targeted functional nanoparticles, the develop-
ment and potential applications of nanoscale blueprints 
in medical management and diagnosis, the use of nano-
particles for stem cell tracking, differentiation, biosensing, 
transplantation, magnetic nanoparticle and quantum dot-
based applications in tissue engineering and stem cells 
in humans, similar to nano-regenerative medicine.21 
 
Nanoparticles for siRNA Delivery. Some requirements 
of nanoparticles to permit small interfering RNA (siRNA) 
consignment into the tumour include being very minuscule 
(size no bigger than 1000 nm), biocompatible, biodeg-
radable, depletion of immuno stimulatory properties, and 
can avoid rapid hepatic/renal clearance. Some of them 
are lipid complex (cationic liposomes, lipoplexes, etc.), 
conjugated polymers (cholesterol, polymer-PEG, etc.), 
and cationic polymers (chitosan, atelocollagen, etc.).22 
 
Nanoparticles serve as conveyance vectors for siRNA 
and present plentiful benefits over stripped siRNA 
conveyance because of its capability to adjust siRNA 
while disseminating higher groupings of siRNA, spe-
cifically into tumour destinations. Furthermore, some of 
these nanoparticles can be changed with high fondness 
ligands to correctly target siRNA, specifically in the tumour. 
These nanoparticles can serve to advance controlled 
discharge, and when planned accurately they can give a 
protected and solid stage for siRNA conveyance for the 
management of cancer and other disorders.23, 24 
 
Nanopores. The stream of DNA via nanopores can be 
utilised to separate low duplicate quantities of DNA, 
allowing extremely fast genome sequencing. The primary 
exhibit of this guideline utilised a variety of round and 
hollow gold nanotubules with inward widths as little as 
1.6 nanometres. Positive ions were rejected, and negative 
ions were transported through the membrane at the point 
when the tubules were charged positively. Interestingly, 
only positive ions went through when the film was 
adversely charged.25 Recently, nanopore-based 
electrochemical and nucleic acids sensors can be used to 
detect nucleic acids selectively. It is a potentiometric 
sensing blueprint from Nernst–Planck/Poisson 
perspective for nucleic acid hybridisation.26 
 
Nanodots. Fluorescent nanoparticles, for example, 
'quantum dots',27 PEBBLES (probes encapsulated by 
biologically localised embedding) and perfluorocarbon 
particles, possibly conquer these issues. ‘Quantum dot' 
nanocrystals',28 for the case, are made to a few nano-
metres in diameter with an almost boundless scope of 
pointedly characterised hues. The particles are edgy, 
utilising white light and can be connected to biomolecules 
to frame seemingly perpetual delicate probes. On a 
fundamental level, separate natural occasions can be 
checked, all the while labelling distinctive proteins or 
DNA sequences with nanodots of a particular colour. 
Nanodots are suitable platforms for advancement of 
photoluminescence-based sensing schemes.29 
  
Nanotheragnostic. Nanotheragnostic (theragnostic nano-
particles), or theragnostic nanomedicines, are incorporated 
nano particulate frameworks that analyse, convey a focus 
on treatment, and screen reactions to treatment.30 
Nanotheragnostic regimens are useful for management 
of cancer, inflammatory liver disease,31 cardiovascular 
diseases (i.e. atherosclerosis, thrombosis), and have a 
promising application in arthritis (e.g. rheumatoid arthritis), 
neurodegenerative diseases, age-related macular degenera-
tion, psoriasis, atherosclerosis, and various bloodstream 
bacterial infections.32,33 
 
The four fundamental components that ought to be 
satisfied in the structure of nanotheragnostics are the 
biodegradable nanocarrier material (based on hybrid 
materials, an inorganic component, and an organic matrix), 
the signal emitter or imaging agent (exclusive optical, 
magnetic, or radioactive hallmark), the medication or 
remedial molecule, and changes to the later component 
based on passive-active delivery strategies.34, 35 
Magnificently, theragnostic nanotools would result in a 
multimodality imaging procedure mixed with a multi-
drug nanocarrier, in addition to supplementary treatment 
techniques (i.e. photodynamic treatment, hyperthermia, 
and photothermal treatment). Nanotheragnostics and 
image-guided drug delivery are relied upon to empower 
"precise and personalised" medicine.35,36 
 
Nanodrugs and Targeting Mechanisms. Nanodrugs in 
destructive tissues has uptake and aggregation. The two 
can happen through two systems, i.e. "uninvolved focusing 
on" and "dynamic focusing on". Aloof focusing on 
depends on both the size of the medication bearers and 
the cracked neovasculature of the tumour. Inactive 
aggregation at the tumour site is anticipated to occur 
through Enhanced Permeability and Retention (EPR) 
effect. With the more drawn out blood course time 
accomplished by stealth alteration (e.g. PEGyla tion), 
expanded gathering of NPs is conceivable through the 
EPR effect. EPR happens because of the expanded 
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vessel defectiveness and debilitated lymphatic function 
typically observed in tumour tissue; this allows nano-
materials to enter and amass there.21,37,38 
 
Dynamic focusing of nanomaterials is being inves 
tigated as a strategy to allow spatial localisation by 
purposefully homing NPs to actively diseased regions 
while obliterating off-target adverse effects in healthy 
tissue. It is achieved by functionalization of their 
surface with bioactive molecules, using engineered 
antibodies, transferrin, folic acid, and enzymes which 
perceive and interplay with cancer-specific targets 
overexpressed on the surface of cancerous cells.39 
 
The recent bioactive molecule, QD242-encapsulated 
polymeric nanoparticles (NPs) functionalised with a 
peptide (Cys-Plec-1 targeted peptides or cys-PTP), carefully 
fastened to Plectin-1 (Plec-1). Plec-1 is a Biomarker of 
Pancreatic ductal adenocarcinoma (PDAC).40 Active 
targeting to accomplish efficacious nanome dicine 
congeries in tumour tissue is confutable, as some experts 
strive to construct original and creative approaches for 
active tumour targeting.21,31 The most commonly used 
targeting moieties are mono-clonal antibodies or antigen 
binding fragments, antibody fragments, and single chain 
variable fragments for active targeting. The latter being 
favoured because of its decreased immunogenicity and 
high target specificity.21,31 
 
Aptamer Nanomedicine. Aptamer nanomedicine is a 
rising, and propitious class of therapeutics used to locate 
the difficulties faced by recent cancer treatments. It 
might address restrictiveness of different ligands for 
targeted treatment in oncology and profoundly perfect 
with combined medication treatment. Nevertheless, the 
strategy would require a better comprehension of drug-
loading efficiency, drug-releasing mechanisms, and carrier 
design.41,42 
 
Micro-RNA (miRNA), small hairpin RNA (shRNA), small 
interfering RNA (siRNA), and antisense oligonucleotides 
are engineered for knocking down a specific gene 
(deleting a gene function) to murder definite types of 
cells. Conversely, plasmid DNA or mRNA are used for 
transfection to deliver a certain gene (enumerating a 
gene function) to heal a disease. Up to now, most 
research focuses on the development of aptamer-
mediated miRNA, shRNA, or siRNA delivery systems 
for gene silencing applications. This is an emerging 
class of gene therapy that is particularly reassuring for 
cancer treatment.41,42 
 
The antinucleolin aptamer, AS1411, coupled to this 
liposomal design, for breast cancer cell targeting, executed 
cancer cells with high specificity. This aptamer-doxoru-
bicin liposome formulation hindered breast tumour 
growth prompted by oestrogen, as no significant or 
important growth of the tumour was detected in the 
group treated with the aptamer-doxorubicin liposome, 
while the size of the tumour in the control group raised 
166%.21,43,44 Another example is 5-fluorouracil (5-FU) 
combined with AS1411 aptamer (NP-5-FU-APTAS1411), 
which can be used to effectively manage gastric cancer.45 
 
Related to drug delivery, the most effortless strategy for 
aptamer-based nucleic acid delivery is to connect the 
therapeutic nucleic acid directly to the aptamer. This is 
famous as an aptamer-therapeutic nucleic acid chimaera. 
The experts have created functional DNA nano structures 
to convey the chemotherapy medication to resistant 
cancer cells. These nanostructures comprise of two 
components, a DNA aptamer and a double-stranded 
DNA (dsDNA). Recently, nucleic acid–based nano 
devices have prompted energising molecular biotech 
nologies to the top of the line biological imaging.42, 46, 47 
 
The chimaeras Chi-29b and GL21.T-let are supple 
mentary examples of direct conjugation of the aptamer 
to a therapeutic nucleic acid. Chi-29b consists of an 
antimucin 1 (MUC1) aptamer and miRNA miR-29b for 
ovarian cancer treatment.21,42,48 It becomes illuminating 
that the critical steps for clinical translation of 
nanotherapeutics need further inter national and 
interdisciplinary efforts, where the entire stakeholder 
community is involved from bench to bedside. The 
period of nanomedicine is ready to develop and mature 
in the following couple of decades; integrating elements 
of personalised and precision medicine. It will influence 
the therapeutic world in an effective and everlasting 
way.  
 
Transcriptomics Tools for Nanomedicine. The design 
of nanobiomedicine-based drugs could only be feasible 
with the certain incorporation of solid assistant tools.49 
Bioinformatics, as the interdisciplinary field of biology 
and computer science, is playing a cardinal role in 
designing nanobiomedicine-based drugs.50,51 Due to the 
rising importance of the transcriptomics approach, 
bioinformatics is adjusted to cope with this development 
as well.52 The Vienna RNA Package is one of the tools 
that could be utilised to design siRNA.53 The theoretical 
basis for siRNA design is a solid comprehension of 
chemical kinetics and thermodynamics, especially the 
modelling of transition states between compounds.54 
The Vienna RNA Package also provides tools for 
secondary structure prediction, multiple sequence 
alignments, and others. However, the rising importance 
of transcriptomics is still strongly correlated with the 
recent advances in proteomics. The important role of 
Transcription factor proteins, such as Dicer and Argonout, 
for regulating non-coding (NC)RNA is still considered by 
the scientific community as important.55 Comprehension 
of Protein Domain annotation would eventually shed 
light to the narration of the transcriptomics mechanistic 
insights.56 Thus, the dynamism of nucleic acids has 
already been unveiled with the DNA-biped nano-
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modeling.57 These theoretical bases are important as the 
cornerstone for nanobiomedicine-based drug development.  
 
The application of transcriptomics-based bioinformatics 
in drug design is already in sight. Pharmaceutical research 
has provided the clinical application for cancer, HIV/ 
AIDS, hepatitis, and others.58 However, due to the 
incomplete understanding of nano-based modelling of 
drug-target interaction, only a handful of products are 
available on the market.58 The different nature of 
molecules in nano-scale size should be considered when 
constructing a solid computational model. Thus, a new 
field that incorporates bioinformatics and nanomedicine 
has already born. Nanoinformatics is the intersection 
between bioinformatics and nanobiotechnology.59 The 
advancements in nanomaterials have made it possible to 
scale them into the realm of nanobiomedicine.60 However, 
real applications of nanoinformatics remain to be seen. 
These nano-based computations need strong compu-
tational power as provided in the computer clusters and 
supercomputers.61 
 
Proteomics-based Computation for nanobiome dicine-
based Drug Design. The growing field of transcripto-
mics still needs advancement in proteomics. Most of the 
drugs in the market still target protein receptors and 
enzymes for knock-down of the disease. Three important 
methods for the computation of drug design, namely 
Molecular Docking, Molecular Dynamics, and ADMET 
are constructing their models based upon protein-ligand 
interactions.62-64 Molecular docking method has success-
fully simplified the labourous High Throughput Screening 
(HTS) process that is necessary to identify the most 
feasible lead compound. Meanwhile, molecular dynamics 
has given vivid illustrations towards the mechanistic 
insights of molecular interactions. ADMET computation 
has simplified the research of drug metabolism as well. 
The commonly used drug types are natural products, 
semi-synthetic, and synthetic molecules.65,66 Some ground-
breaking drug candidates are peptide and nucleotide-
based molecules.67,68 The comprehension of the molecular 
mechanism on a sub-atomic level with those methods will 
always be an important contribution to the advancement 
of modern drug design. 
 
Future of Bionanomedicine: Intersection of Big Data 
and Automatisation of Laboratory protocols. On one 
side, the growing data and tools of sophistication of 
GenBank will enable researchers to compute the best 
information to the scientific community. On the other 
side, increasing automatisation of laboratory protocols 
will release the researcher from the laborious hours of 
bench work. In the end, the researcher could be more 
focused on the novelty of their idea, and less on the 
laborious techniques. Nanobiomedicine is the interface 
between basic science and applied science, and also 
between computational and wet laboratory methods. 
This multidisciplinary effort could be a major trend in 




Special thanks to Mr Vicente Rey-Valenzuela, PhD. 
Plant Pathologist at Cenibanano - Augura, Colombia, 
for his help in getting relevant journals and references. 
 
Conflicts of Interest Statement 
 
The Authors declare that there is no conflict of interest 




1. Feynman R. There is plenty of room at the bottom: an 
invitation to enter a new field of physics. Reprinted in: 
Crandall BC, Lewis J (eds) Nanotech nology: Research 
And Perspectives., Cambridge, MA: The MIT Press; 1992. 
p.347-363. 
2. Sanna V, Pala N, Sechi M. Targeted therapy using 
nanotechnology: focus on cancer. Int J Nanomed. 
2014;9:467-83. 
3. Kunjachan S, Ehling J, Storm G, Kiessling F, Lam mers T. 
Noninvasive Imaging of Nanomedicines and Nanothera-
nostics: Principles, Progress, and Prospects. Chem Rev. 
2015;115:10907-37 
4. Jagtap P, Sritharan V, Gupta S. Nanotheranostic ap 
proaches for management of bloodstream bacterial 
infections. Nanomedicine. 2017;13:329-41. 
5. Dai Z (Ed.). 2016. Advances in Nanotheranostics II: 
Cancer Theranostic Nanomedicine. Singapore: Springer.  
6. Schwartz S. Unmet needs in developing nano particles for 
precision medicine. Nanomedicine. 2017;12:271-4 
7. Carmen C, Valentina G, Mariana CC, Keng-Shiang H, 
Florin I, Yu-Mei L, et al. Nanostructured Approaches for 
the Targeted Delivery of Antibiotics in Difficult Infections. 
Curr Org Chem. 2017;21:45-52. 
8. Hoop M, Mushtaq F, Hurter C, Chen XZ, Nelson BJ, Pané 
S. A smart multifunctional drug delivery nano platform for 
targeting cancer cells. Nanoscale. 2016;8:12723-8. 
9. Kateb B, Chiu K, Black KL, Yamamoto V, Khalsa B, 
Ljubimova JY, et al. Nanoplatforms for constructing new 
approaches to cancer treatment, imaging, and drug 
delivery: what should be the policy? Neuroimage. 2011;54 
Suppl 1:S106-24. 
10. Venuta A, Wolfram J, Shen H, Ferrari M. Post-nano 
strategies for drug delivery: multistage porous silicon 
microvectors. J Mater Chem B. 2017;5:207-19. 
11. Da Róz AL, Ferreira M, de Lima Leite F, Oliveira ON. 
2017. Nanostructures. Cambridge, MA: Elsevier. 
12. Moradi-Kalbolandi S, Habibi-Anbouhi M, Golkar M, 
Behdani M, Rezaei G, Ghazizadeh L, et al. Development 
of a novel engineered antibody targeting human CD123. 
Anal Biochem. 2016;511:27-30. 
13. Chen Y, Xianyu Y, Jiang X. Surface Modification of Gold 
Nanoparticles with Small Molecules for Biochemical 
Analysis. Acc Chem Res. 2017;50:310-9 
14. Schaufler V, Czichos-Medda H, Hirschfeld-Warnecken V, 
Neubauer S, Rechenmacher F, Medda R, et al. Selective 
binding and lateral clustering of α5β1 and αvβ3 integrins: 
Anurogo, et al. 
Makara J. Health Res.  August 2017 | Vol. 21 | No. 2 
46 
Unravelling the spatial requirements for cell spreading and 
focal adhesion assembly. Cell Adhes Migration. 2016.  
15. Liu G, Li K, Luo Q, Wang H, Zhang Z. PEGylated 
chitosan protected silver nanoparticles as water-borne 
coating for leather with antibacterial property. J Colloid 
Interface Sci. 2017;490:642-51. 
16. Sandri G, Motta S, Bonferoni MC, Brocca P, Rossi S, 
Ferrari F, et al. Chitosan-coupled solid lipid nanoparticles: 
Tuning nanostructure and muco adhesion. European J of 
Pharmaceut Biopharm. 2017;110:13-8.  
17. Shitrit Y, Bianco-Peled H. Acrylated chitosan for 
mucoadhesive drug delivery systems. Int J Pharm. 
2017;517:247-55.  
18. Wang J, Kong M, Zhou Z, Yan D, Yu X, Cheng X, et al. 
Mechanism of surface charge triggered intestinal epithelial 
tight junction opening upon chitosan nanoparticles for 
insulin oral delivery. Carbohydr Polym. 2017;157:596-602.  
19. Shete G, Modi SR, Bansal AK. Effect of Mannitol on 
Nucleation and Crystal Growth of Amorphous Flavonoids: 
Implications on the Formation of Nanocrystalline Solid 
Dispersion. J Pharm Sci. 2015;104:3789-97. 
20. Xiao H, Fei-Fei Y, Xiao-Lan W, Guang-Yin Y, Chun-Yu L, 
Ying Z, et al. Curcumin Acetate Nanocrystals for Sustained 
Pulmonary Delivery: Preparation, Characterization and In 
Vivo Evaluation. J Biomed Nanotechnol. 2017;13:99-109. 
21. Igarashi E. 2015.  Nanomedicines and Nanopro ducts: 
Applications, Disposition, and Toxicology in the Human 
Body. CRC Press. Taylor & Francis Group. USA. 
22. Wan Y, Moyle PM, Gn PZ, Toth I. Design and evaluation 
of a stearylated multi component peptide-siRNA 
nanocomplex for efficient cellular siRNA delivery. 
Nanomedicine. 2017;12:281-93. 
23. Corbet C, Ragelle H, Pourcelle V, Vanvarenberg K, 
Marchand-Brynaert J, Préat V, et al. Delivery of siRNA 
targeting tumor metabolism using non-covalent PEGylated 
chitosan nanoparticles: Identifi cation of an optimal 
combination of ligand structure, linker and grafting 
method. J Control Release. 2016;223:53-63. 
24. Yan Y, Zhou K, Xiong H, Miller JB, Motea EA, Boothman 
DA, et al. Aerosol delivery of stabilized polyester-siRNA 
nanoparticles to silence gene expression in orthotopic lung 
tumors. Biomaterials. 2017;118:84-93. 
25. Edel JB, Albrecht T. 2013.  Engineered Nanopores for 
Bioanalytical Applications. Waltham, MA: Elsevier.  
26. Makra I, Brajnovits A, Jágerszki G, Fürjes P, Gyurcsányi 
R. Potentiometric sensing of nucleic acids using chemically 
modified nanopores. Nanoscale. 2017;9:739-47. 
27. Prando G. Qubits in a row. Nature Nanotechnology. Phys 
Rev Appl. 2016;6:054013.  
28. Credi A (Ed.). 2017. Photoactive Semiconductor Nano-
crystal Quantum Dots: Fundamentals and Applications. 
Springer. Switzerland. ISBN 978-3-319-51192-4. 
29. Rodrigues SSM, Riberio DSM, Soares JX, Passos MLC, 
Saraiva MLMFS, Santos JLM. Application of 
nanocrystalline CdTe quantum dots in chemical analysis: 
Implementation of chemo-sensing schemes based on 
analyte-triggered photoluminescence modulation. Coord 
Chem Rev. 2017;330:127-43. 
30. Devasena T. Diagnostic and Therapeutic Nanomaterials. 
In: Therapeutic and Diagnostic Nanomaterials. Singapore: 
Springer; 2017. p. 1-13. 
31. Bartneck M, Tacke F. Targeted Modulation of Macrophage 
Functionality by Nanotheranostics in Inflammatory Liver 
Disease and Cancer. In: The Immune Response to 
Implanted Materials and Devices. Switzerland: Springer 
International Publishing. 
32. Evangelopoulos M, Tasciotti E. Bioinspired approaches 
for cancer nanothera nostics. Nanomedicine. 2017;12:5-7.   
33. Jagtap P, Sritharan V, Gupta S. Nanotheranostic approaches 
for management of bloodstream bacterial infections. 
Nanomedicine: Nanotechnology. Bio Med. 2017;13:329-41. 
34. Arias JL. Drug Targeting by Magnetically Respon sive 
Colloids. New York: Nova Science Publishers Inc; 2010. 
35. Jabr-Milane LS, LE van Vlerken, S Yadav, MM Amiji. 
Multifunctional nanocarriers to overcome tumor drug 
resistance. Cancer Treat Rev. 2008;34:592-602. 
36. Fang C, M Zhang. Nanoparticle-based theragnostics: 
Integrating diagnostic and thera peutic potentials in 
nanomedicine. J Control Release. 2010;146:2-5. 
37. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer 
nanomedicine: progress, challenges and opportunities. Nat 
Rev Cancer. 2017;17:20-37.  
38. Nakamura Y, Mochida A, Choyke PL, Kobayashi H.. 
Nanodrug Delivery: Is the Enhanced Permeability and 
Retention Effect Sufficient for Curing Cancer? 
Bioconjugate Chem. 2016;27:2225-38. 
39. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer 
nanomedicine: from targeted delivery to combination 
therapy. Trends Mol Med. 2015;21:223-32. 
40. Sanna V, Nurra S, Pala N, Marceddu S, Pathania D, 
Neamati N, et al. Targeted Nanoparticles for the Delivery 
of Novel Bioactive Molecules to Pancreatic Cancer Cells. 
J Med Chem. 2016;59:5209-20. 
41. Godsey ME, Suryaprakash S, Leong KW. Materials 
Innovation for Co-delivery of Diverse Therapeutic Cargos. 
RSC Adv. 2013;3:24794-811. 
42. Lao YH, Phua KKL, Leong KW. Aptamer Nanomedicine 
for Cancer Therapeutics: Barriers and Potential for 
Translation. ACS Nano. 2015;9:2235-54. 
43. Karagkiozaki V, Logothetidis S (Eds). Horizons in Clinical 
Nanomedicine. 2014. USA: CRC Press. Taylor & Francis 
Group; 2015. p. 2235-54. 
44. Charoenphol P, Bermudez H. Aptamer-Targeted DNA 
Nanostructures for Thera peutic Delivery. Mol Pharmaceut. 
2014;11:1721-5. 
45. Behrooz AB, Nabavizadeh F, Adiban J, Ardestani MS, 
Vahabpour R, Aghasadeghi MR, et al. Smart bomb AS1411 
aptamer-functionalized/PAMAM dendrimer nanocarriers 
for targeted drug delivery in the treatment of gastric 
cancer. Clin Exp Pharmacol Physiol. 2017;44:41-51. 
46. Liu J, Wei T, Zhao J, Huang Y, Deng H, Kumar A, et al. 
Multifunctional aptamer-based nanoparticles for targeted 
drug delivery to circumvent cancer resistance. Biomaterials. 
2016;91:44-56. 
47. Chakraborty K, Veetil AT, Jaffrey SR, Krishnan Y. Nucleic 
Acid–Based Nanodevices in Biological Imaging. Annu 
Rev Biochem. 2016;85:349-73. 
48. Muluhngwi P, Richardson K, Napier J, Rouchka EC, Mott 
JL, Klinge CM. Regulation of miR-29b-1/a transcription 
and identification of target mRNAs in CHO-K1 cells. Mol 
Cell Endocrinol. 2017;444:38-47. 
49. Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for 
protein delivery: Overview and perspec tives. J Control 
Release. 2016;240:24-37. 
50. D'Mello SR, Das SK, Das NG. Polymeric nanoparticles for 
small-molecule drugs. in Y. Pathak and D. Thassu, (Eds.) 
Drug Delivery Nanoparticles Formulation and Charac-
terization. New York: Informa Healthcare; 2009. p. 16-34. 
Bionanomedicine: A “Panacea” In Medicine? 
Makara J. Health Res.  August 2017 | Vol. 21 | No. 2  
47
51. Schönbach C, Nakai K, Tan TW, Ranganathan S. 2010;11. 
InCoB2010-9th International Conference on Bioin-
formatics at Tokyo, Japan, September 26-28, 2010. BMC 
Bioinformatics. Suppl 7 (SUPPL. 7):S1. 
52. Dong Z, Chen Y. Transcrip tomics: advances and 
approaches. Sci China Life Sci. 2013;56:960-7. 
53. Gruber AR, Bernhart SH, Lorenz R. The viennaRNA web 
services. In: RNA Bioinformatics. 2015:307-26. 
54. Hofacker IL, Stadler PF. Memory efficient folding 
algorithms for circular RNA secondary structures. 
Bioinformatics. 2006;22:1172-6.  
55. Parikesit AA, Steiner L, Stadler PF, Prohaska SJ. Pitfalls 
of Ascertainment Biases in Genome Annotations—
Computing Comparable Protein Domain Distributions in 
Eukarya. Malaysian J Fundam Appl Sci. 2014;10:65-75. 
56. Parikesit AA, Stadler PF, Prohaska SJ. Evolution and 
Quantitative Compa rison of Genome-Wide Protein 
Domain Distribu tions. Genes (Basel). 2011;2:912-24.  
57. Ben-Ari I, Boushaba K, Matzavinos A, Roitershtein A. 
Stochastic Analysis of the Motion of DNA Nano-
mechanical Bipeds. Bull Math Biol. 2011;73:1932-51.  
58. Burnett JC, Rossi JJ. RNA-based therapeutics: current 
progress and future prospects. Chem Biol. 2012;19:60-71.   
59. González-Nilo F, Pérez-Acle T, Guínez-Molinos S, Geraldo 
DA, Sandoval C, Yévenes A, et al. Nanoinformatics: an 
emerging area of infor mation technology at the intersection 
of bioinfor matics, computational chemistry and nanobio 
technology. Biol Res. 2011;44:43-51.  
60. Maojo V, Fritts M, Martin-Sanchez F, De la Iglesia D, 
Cachau RE, Garcia-Remesal M, et al. Nanoinformatics: 
developing new computing applications for nanomedicine. 
Computing. 2012;94:521-39.  
61. Akbar Z, Handoko LT. GRID architecture through a public 
cluster. In: 2008 International Conference on Computer 
and Communication Engineering. IEEE. 2008:1016-8.  
62. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking 
and scoring in virtual screening for drug discovery: methods 
and applications. Nat Rev Drug Discov. 2004;3:935-49. 
63. Karplus M. Molecular dynamics of biological macro-
molecules: a brief history and perspective. Biopolymers. 
2003;68:350-8. 
64. van de Waterbeemd H, Gifford E. ADMET in silico 
modelling: towards prediction paradise? Nat Rev Drug 
Discov. 2003;2:192-204. 
65. Parikesit AA, Ardiansah B, Handayani DM, Tambunan 
USF, Kerami D. Virtual screening of Indonesian flavonoid 
as neuraminidase inhibitor of influenza a subtype H5N1. 
IOP Conf Ser Mater Sci Eng. 2016;107:012053.  
66. Kampmann T, Yennamalli R, Campbell P, et al. In silico 
screening of small molecule libraries using the dengue 
virus envelope E protein has identified compounds with 
antiviral activity against multiple flaviviruses. Antiviral 
Res. 2009;84:234-41.  
67. Soltero R. Oral Protein and Peptide Drug Delivery. In: 
Wang B, Siahaan TJ, Soltero R, eds. Drug Delivery: 
Principles and Application. John Wiley & Sons, Inc;  
2005. p.189-200. 
68. Julander JG, Bantia S, Taubenheim BR, et al. BCX4430, a 
novel nucleo side analog, effectively treats yellow fever in a 
Hamster model. Antimicrob Agents Ch. 2014;58:6607-14.  
 
